[1]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-JP5806438,2015,B1Locationinpatent:Paragraph0751;0752
[2]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-WO2022/9911,2022,A1Locationinpatent:Paragraph0091-0092;0094
Title: Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW.